Akebia Therapeutics, Inc. (AKBA) earnings
AKBA earnings moved a median of +0.58% by the close. Quarterly and annual AKBA reports and results, each read against the price at its own news timestamp. Back to the AKBA overview →
30 measured AKBA earnings events.
Where these AKBA earnings landedvs 30 measured AKBA earnings reactions
| Middle 50% of AKBA earnings reactions | -4.65% to +4.42% |
|---|---|
| Median reaction (to close) | +0.58% |
| Measured reactions | 30 |
Point-in-time · zero look-ahead
Half of the 30 AKBA earnings events with a measured close landed between -4.65% and +4.42%; 53% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights | Press release | +7.13% | +8.20% | |
| Form 10-Q Akebia Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +7.13% | +8.20% | |
| Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights | Press release | +1.19% | +0.00% | |
| Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights | Press release | +3.98% | +4.42% | |
| Form 10-Q Akebia Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +3.98% | +4.42% | |
| Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights | Press release | +0.36% | +0.00% | |
| Form 10-K Akebia Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -7.19% | -9.59% | |
| Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Press release | -3.18% | -3.47% | |
| Form 10-Q Akebia Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -3.18% | -3.47% | |
| Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights | Press release | +4.31% | +0.48% | |
| Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | Press release | -5.21% | -5.05% | |
| Form 10-Q Akebia Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -5.21% | -5.05% | |
| Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights | Press release | -0.14% | +0.68% | |
| Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | Press release | -1.61% | -6.43% | |
| Form 10-Q Akebia Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -1.61% | -6.43% | |
| Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights | Press release | -1.04% | -0.83% | |
| Form 10-K Akebia Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.89% | -6.11% | |
| Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Press release | -2.89% | +7.80% | |
| Form 10-Q Akebia Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -2.89% | +7.80% | |
| Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights | Press release | -0.29% | -0.59% | |
| Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | Press release | -4.31% | +2.59% | |
| Form 10-Q Akebia Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -4.31% | +2.59% | |
| Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights | Press release | -2.42% | +0.81% | |
| Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | Press release | -0.90% | +19.82% | |
| Form 10-Q Akebia Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.90% | +19.82% | |
| Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights | Press release | +0.79% | +3.17% | |
| Form 10-K Akebia Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.25% | +6.25% | |
| Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights | Press release | -6.31% | -6.80% | |
| Form 10-Q Akebia Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -6.31% | -6.80% | |
| Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights | Press release | +1.28% | +2.50% |
Keep exploring
More AKBA: analyst actions → · SEC filings → · AKBA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Albireo Pharma, Inc. (ALBO) | 378 | +0.05% | 53% |
| REPRO MED SYSTEMS INC (REPR) | 378 | 0.00% | 26% |
| Amneal Pharmaceuticals, Inc. - Class A (AMRX) | 377 | -0.08% | 46% |
| Autolus Therapeutics plc - American Depositary Shares (AUTL) | 377 | -0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.